XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Note M - Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2018
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | M . Segment Information Our business consists of two segments for financial reporting purposes. The two segments are identified as (i) private-label contract manufacturing, which primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn® and SR CarnoSyn® trade names. We evaluate performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to: human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. Transfers of raw materials between segments are recorded at cost. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A. Our operating results by business segment for the years ended June 30 were as follows (in thousands):
|  | 201 8 |  |  | 201 7 |
Net Sales |  |  |  |  |  |  |  |
Private-label contract manufacturing |  | $ | 110,992 |  |  | $ | 95,024 |
Patent and trademark licensing |  |  | 21,445 |  |  |  | 26,922 |
|  | $ | 132,437 |  |  | $ | 121,946 |
|  | 201 8 |  |  | 201 7 |
Income from Operations |  |  |  |  |  |  |  |
Private-label contract manufacturing |  | $ | 10,482 |  |  | $ | 8,569 |
Patent and trademark licensing |  |  | 5,730 |  |  |  | 7,534 |
Income from operations of reportable segments |  |  | 16,212 |  |  |  | 16,103 |
Corporate expenses not allocated to segments |  |  | (6,679 | ) |  |  | (6,401 | )
|  | $ | 9,533 |  |  | $ | 9,702 |
|  | 201 8 |  |  | 201 7 |
Assets |  |  |  |  |  |  |  |
Private-label contract manufacturing |  | $ | 69,037 |  |  | $ | 60,489 |
Patent and trademark licensing |  |  | 16,170 |  |  |  | 12,122 |
|  | $ | 85,207 |  |  | $ | 72,611 |
Our private-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Australia, New Zealand, and Asia. Our primary markets outside the U.S. are Europe and Asia. Our patent and trademark licensing activities are primarily based in the U.S. Net sales by geographic region, based on the customers’ location, for the two years ended June 30 were as follows (in thousands):
|  | 201 8 |  |  | 201 7 |
United States |  | $ | 65,482 |  |  | $ | 63,104 |
Markets outside the United States |  |  | 66,955 |  |  |  | 58,842 |
Total net sales |  | $ | 132,437 |  |  | $ | 121,946 |
Products manufactured by NAIE accounted for 81% of consolidated net sales in markets outside the U.S. in fiscal 2018 and 59% in fiscal 2017. No products manufactured by NAIE were sold in the U.S. during the fiscal years ended June 30, 2018 and 2017. Assets and capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, for the two years ended June 30 were as follows (in thousands):
201 8 |  | Long-Lived Assets |  |  | Total Assets |  |  | Capital Expenditures |
United States |  | $ | 10,887 |  |  | $ | 51,562 |  |  | $ | 1,564 |
Europe |  |  | 8,403 |  |  |  | 33,645 |  |  |  | 2,517 |
|  | $ | 19,290 |  |  | $ | 85,207 |  |  | $ | 4,081 |
201 7 |  | Long-Lived Assets |  |  | Total Assets |  |  | Capital Expenditures |
United States |  | $ | 10,753 |  |  | $ | 47,777 |  |  | $ | 2,365 |
Europe |  |  | 7,383 |  |  |  | 24,834 |  |  |  | 2,989 |
|  | $ | 18,136 |  |  | $ | 72,611 |  |  | $ | 5,354 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration